2023 ASCO前瞻 | 泌尿肿瘤领域重磅研究及中国研究一览

一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模大、学术水平高、具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床新研究为特点，讨论当前国际先进的治疗方法。医脉通精选了泌尿肿瘤领域Oral Abstract Session部分的13项重磅研究及Poster Session部分入选的8项中国研究，小编带您先睹为快。

口头报告专场（Oral Abstract Session）

前列腺/睾丸/阴茎肿瘤

摘要号：LBA5000

标题：Prostate irradiation in men with de novo, low-volume, me[x]tastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

报告人：Alberto Bossi

摘要号：5004

标题：TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with me[x]tastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

报告人：Karim Fizazi

摘要号：5005

标题：LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with me[x]tastatic castration resistant prostate cancer (mCRPC).

报告人：Shahneen Sandhu

口头报告专场（Oral Abstract Session）

LBA4619的演示及讨论

摘要号：LBA4619

标题：Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or me[x]tastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

报告人：Yohann Loriot

口头报告专场（Oral Abstract Session）

肾脏/膀胱肿瘤

摘要号：LBA4500

标题：Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in me[x]tastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

报告人：Toni K. Choueiri

摘要号：LBA4501

标题：Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

报告人：Brian I. Rini

摘要号：4502

标题：Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

报告人：Thomas E. Hutson

摘要号：4503

标题：Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with me[x]tastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.

报告人：Enrique Grande

摘要号：4504

标题：Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with me[x]tastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

报告人：Arlene O. Siefker-Radtke

摘要号：4505

标题：Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or me[x]tastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

报告人：Shilpa Gupta

摘要号：4506

标题：Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

报告人：Robert J. Motzer

摘要号：LBA4507

标题：Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.

报告人：Christian Pfister

摘要号：LBA4508

标题：SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

报告人：Seth P. Lerner

壁报专场（Poster Session）

前列腺/睾丸/阴茎肿瘤

摘要号：5057

海报号：151

标题：Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with me[x]tastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.

报告人：朱耀，复旦大学附属肿瘤医院

摘要号：5065

海报号：159

标题：Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.

报告人：叶定伟，复旦大学附属肿瘤医院

壁报专场（Poster Session）

肾脏/膀胱肿瘤

摘要号：4521

海报号：13

标题：Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.

报告人：戴洪海，山东省立医院

摘要号：4533

海报号：25

标题：Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligome[x]tastatic renal cell carcinoma.

报告人：刘洋，中山大学肿瘤防治中心

摘要号：4543

海报号：35

标题：Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in me[x]tastatic renal cell carcinoma.

报告人：Honglei Cui，中国医学科学院肿瘤医院

摘要号：4566

海报号：58

标题：Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or me[x]tastatic urothelial carcinoma: An open-label phase 1b/2 study.

报告人：盛锡楠，北京大学肿瘤医院

摘要号：4585

海报号：77

标题：Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.

报告人：林天歆，中山大学孙逸仙纪念医院